Boston-based firm Adicet Bio, Inc. is a clinical stage biotechnology company that specializes in the discovery and development of allogeneic gamma delta T cell therapies for cancer and other ailments. By engineering gamma delta T cells with chimeric antigen receptors and chimeric adaptors, the company aims to improve selective tumor targeting, facilitate adaptive immune response, and enhance persistence for long-term efficacy in patients. Among Adicet Bio's pipeline products is the Phase I clinical study drug ADI-001, designed to treat non-Hodgkin's lymphoma. Additionally, the company is developing ADI-002, which is in preclinical trials for various solid tumors, and the novel engineered CAd gamma delta T cell product candidate ADI-925, which targets tumor stress ligands.
Adicet Bio's ticker is ACET
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 501-1000 employees working at Adicet Bio
It is adicetbio.com/about
Adicet Bio is in the Basic Materials sector
Adicet Bio is in the Chemicals - Major Diversified industry
The following five companies are Adicet Bio's industry peers: